[Scintigraphy of parathyroid adenomas with 99mTc-sestamibi in an endemic goiter area]

Nuklearmedizin. 1994 Jun;33(3):93-8.
[Article in German]

Abstract

Recently 99mTc-Sestamibi (MIBI) has been introduced into parathyroid imaging. The purpose of this study was to evaluate the MIBI scan in an endemic goiter area. 25 patients with primary and 9 with secondary hyperparathyroidism (HPT) underwent a MIBI scan one day prior to surgical exploration of the neck. Cervicothoracic planar scintigraphy was performed 5, 15 and 120 min after i.v. injection of 444 MBq of 99mTc-Sestamibi. The MIBI scan correctly detected 20 of 25 adenomas in 25 patients with pHPT. In only 6 of 9 patients with parathyroid hyperplasia a focal uptake was found. The cause of one false-positive result in the control group was an increased MIBI uptake by a follicular adenoma of the thyroid. Parathyroid scintigraphy using 99mTc-Sestamibi as a single radiopharmaceutical is as sensitive in detecting and localizing parathyroid adenomas as the Tl/Tc-scintigraphy. Due to a high prevalence of thyroid adenomas in an endemic goiter area a higher rate of falsely positive results may be expected.

MeSH terms

  • Adenoma / diagnostic imaging*
  • Adenoma / surgery
  • False Negative Reactions
  • False Positive Reactions
  • Goiter, Endemic / diagnostic imaging*
  • Goiter, Endemic / epidemiology
  • Humans
  • Hyperparathyroidism / diagnostic imaging*
  • Injections, Intravenous
  • Parathyroid Neoplasms / diagnostic imaging*
  • Parathyroid Neoplasms / surgery
  • Prevalence
  • Technetium Tc 99m Sestamibi*
  • Tomography, Emission-Computed / methods*

Substances

  • Technetium Tc 99m Sestamibi